Topical transdermal dexmedetomidine compositions and methods of use thereof

Disclosed is a method of treating or preventing pain in a non-human mammal without sedation, said method comprising: administering to the skin of the non-human mammal a dosage of dexmedetomidine or a pharmaceutically acceptable salt thereof in a range between about 0.05 µg per kg body weight and abo...

Full description

Saved in:
Bibliographic Details
Main Authors SHARR CHRISTOPHER T, KOLENG JOHN J, MACK RANDALL J, HENWOOD GERALDINE A
Format Patent
LanguageEnglish
Published 27.02.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Disclosed is a method of treating or preventing pain in a non-human mammal without sedation, said method comprising: administering to the skin of the non-human mammal a dosage of dexmedetomidine or a pharmaceutically acceptable salt thereof in a range between about 0.05 µg per kg body weight and about 15 µg per kg body weight, wherein said dexmedetomidine or a pharmaceutically acceptable salt thereof is in a pharmaceutically acceptable vehicle in the form of a cream, gel, suspension, foam, lotion, serum, or ointment, and wherein the dexmedetomidine or pharmaceutically acceptable salt thereof is absorbed through the skin and produces analgesia without sedation, such as wherein the non-human mammal is categorised as having a level of sedation that is no greater than level 3 on the Ramsey Sedation Scale during a period of at least six hours immediately after administering the dexmedetomidine or pharmaceutically acceptable salt thereof. Also disclosed is the use of dexmedetomidine or a pharmaceutically acceptable salt thereof in the preparation of a unit dosage of a transdermal analgesic pharmaceutical composition for treating or preventing pain in a mammalian subject without sedation, wherein the unit dosage comprises an amount of dexmedetomidine or a pharmaceutically acceptable salt thereof that is in the range between 0.05 µg per kg body weight of a subject in need thereof and 15 µg per kg body weight of a subject in need thereof, and wherein the pharmaceutical composition is formulated in the form of a cream, gel, suspension, foam, lotion, serum, or ointment for administration to the skin of the mammalian subject in need thereof.
Bibliography:Application Number: NZ20110601195